Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s diseaseACI-35.030, developed using AC Immune’s SupraAntigen® technology, generated rapid, potent polyclonal response against pathological f ...